MacroGenics, Inc.
MGNX
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who haveā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.69
Price-2.38%
-$0.09
1Y
Price
Market Cap
$234.548m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-145.4%
EBITDA Margin-177.0%
Net Profit Margin-174.0%
Free Cash Flow Margin-145.4%
EBITDA Margin-177.0%
Net Profit Margin-174.0%
Free Cash Flow MarginRevenue
$157.082m
+5.1%
1y CAGR+55.1%
3y CAGR+25.8%
5y CAGREarnings
-$70.358m
+5.7%
1y CAGR-215.0%
3y CAGR-138.1%
5y CAGREPS
-$1.10
+6.8%
1y CAGR-205.6%
3y CAGR-131.1%
5y CAGRBook Value
$21.198m
$217.873m
Assets$196.675m
Liabilities$36.509m
DebtDebt to Assets
16.8%
-0.7x
Debt to EBITDAFree Cash Flow
-$71.690m
+13.6%
1y CAGR+2.8%
3y CAGR+5.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company